Brief
Medtech Investment Firm Accelmed Backs Reflux Therapy Company EndoGastric
EndoGastric develops incisionless procedural therapy for gastroesophageal reflux disease
Meir Orbach | 15:27, 28.05.19
Israel-based medtech investment firm Accelmed Growth Partners has joined a funding round of about $45 million for Redmond, Washington-based medical device company EndoGastric Solutions Inc., the two announced Tuesday. Of the sum, Accelmed invested $15 millions. Other participants in the round include Canaan Partners, Chicago Growth Partners, and De Novo Ventures.
Founded in 2003, EndoGastric develops incisionless procedural therapy for gastroesophageal reflux disease.
Based in Israeli central town Herzliya, with additional offices in New York, Accelmed has $350 million in assets under management. Founded in 2009 by Israeli businessmen Mori Arkin and Uri Geiger, the firm invests in small and mid-cap private and public companies in the digital health industry.
No Comments Add Comment